Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma
-
Altmetric Citations
Ellis, Leigh; Pan, Yan; Smyth, Gordon K.; George, Daniel J.; McCormack, Chris; Williams-Truax, Roxamme; Mita, Monica; Beck, Joachim; Burris, Howard; Ryan, Gail; Atadja, Peter; Butterfoss, Dale; Johnstone, Ricky
Description
Purpose: Histone deacetylase inhibitors can alter gene expression and mediate diverse antitumor activities. Herein, we report the safety and activity of the histone deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma (CTCL) and identify genes commonly regulated by panobinostat. Experimental Design: Panobinostat was administered orally to patients with CTCL on Monday, Wednesday, and Friday of each week on a 28-day cycle. A dose of 30 mg was considered excessively toxic, and...[Show more]
Collections | ANU Research Publications |
---|---|
Date published: | 2008 |
Type: | Journal article |
URI: | http://hdl.handle.net/1885/36409 |
Source: | Clinical Cancer Research |
DOI: | 10.1158/1078-0432.CCR-07-4262 |
Download
File | Description | Size | Format | Image |
---|---|---|---|---|
01_Ellis_Histone_deacetylase_inhibitor_2008.pdf | 881.57 kB | Adobe PDF | Request a copy |
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.
Updated: 19 May 2020/ Responsible Officer: University Librarian/ Page Contact: Library Systems & Web Coordinator